Discipline: Biological Sciences
Subcategory: Cancer Research
Romingo Shaw - Southern University at New Orleans
Co-Author(s): Bashir M. Rezk, Iluta Urka, and Romingo Shaw, Southern University at New Orleans, New Orleans, LA Mayank Khanna, Merhan E. Y. Khedr, Zakaria Y. Abd Elmageed, Suresh C. Sikka, and Asim B. Abdel-Mageed, Tulane University, School of Medicine, New Orleans, LA
Treatment of Prostate cancer with radiation and chemotherapeutic agents has been implicated in the induction of collateral damage to the normal tissues and increased risk of osteoporosis, cardiovascular disease, and diabetes. Thus, the strategy to use of such therapy seems to be an undesirable development and a search for agents that would either prevent prostate cancer or cure it without severe side effects is an essential demand. Because of the oxidizability of vitamin E (VE), supplementation with VE often occurs by adding more stable VE esters to VE formulations. Vitamin E succinate (VES) has been identified as a potent and a highly selective anticancer agent. This study has been designed to investigate the effects of VES on highly metastatic C4-2B and PC3 prostate cancer cell lines and compared these effects to RWPE-1 prostate normal cells. Our results showed that VES induced significant apoptotic effects on C4-2B and PC3 prostate cancer cell lines. Co-treatment with bicalutamide had neither synergistic nor additive effects in the androgen sensitive C4-2B prostate cancer cells. Importantly, low concentrations of VES enhanced the growth rate of prostate normal cell, RWPE1. The same findings have been shown with bicalutamide. Furthermore, VES did not alter total GSH and GSSG contents in RWPE-1 normal cells. VES induced proapoptotic effects and increased mitochondrial superoxide anion production in C4-2B and PC3 prostate cancer cell lines. These apoptotic activities were accompanied with reduction of TGSH contents in C4-2B and increased total GSH and GSSG levels in PC3 cells. Antibody array and RT-PCR results showed that VES has differential reduction effects on the expression of antiapoptotic proteins HSP60, HSP70, SVV, XIAP and elevation of expression of a apoptotic protein Smac/DIABLO. In conclusion, our results showed that VES has remarkable and promising selective anticancer effects on the highly bone metastatic prostate cancer cell lines.
Funder Acknowledgement(s): NIH
Faculty Advisor: Bashir M. Rezk,